Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
Eli Lilly CEO Dave Ricks reported that 700,000 new senior patients began GLP-1 treatments following Medicare coverage expansions, with 70% using Lilly products. The GLP-1 market generated $79 billion in 2025 and may hit $190 billion by 2035. These medications helped Eli Lilly become the first pharmaceutical company to reach a $1 trillion valuation. A government-funded study found that GLP-1 medications slow the aging process in mice.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ 700,000 new senior patients began GLP-1 treatments following Medicare coverage expansions
- ✓ 70% of the new senior patients using GLP-1 treatments are on Lilly products
- ✓ The GLP-1 market generated $79 billion in 2025
- ✓ The GLP-1 market may hit $190 billion by 2035
What changed
The government-funded study's findings on GLP-1 medications slowing aging in mice were corroborated, adding to the excitement around the market's potential.
Live updates
-
Eli Lilly CEO: 700,000 seniors started GLP-1s after Medicare coverage
Eli Lilly CEO Dave Ricks reported that 700,000 new senior patients began GLP-1 treatments following Medicare coverage expansions, with 70% using Lilly products. The GLP-1 market generated $79 billion in 2025 and may hit $190 billion by 2035. These medications helped Eli Lilly become the first pharmaceutical company to reach a $1 trillion valuation. A government-funded study found that GLP-1 medications slow the aging process in mice.
Why it matters
The GLP-1 market has seen significant growth, with Eli Lilly emerging as a key player. The company's valuation milestone reflects the market's potential. The aging population and expanding treatment uses are driving interest in GLP-1 medications. The study's findings on aging in mice may have implications for future research and applications.
What is confirmed
- 700,000 new senior patients began GLP-1 treatments following Medicare coverage expansions
- 70% of the new senior patients using GLP-1 treatments are on Lilly products
- The GLP-1 market generated $79 billion in 2025
- The GLP-1 market may hit $190 billion by 2035
- Eli Lilly became the first pharmaceutical company to reach a $1 trillion valuation
- GLP-1 medications slow the aging process in mice
Still unconfirmed
- Growing usage of GLP-1 drugs for weight loss is reshaping how consumers shop for food and clothes
What to watch next
- Eli Lilly's Q3 results
- Further research on GLP-1 medications and aging
- Medicare coverage expansions and their impact on the GLP-1 market
confidence 90%Sources used for this update (4)
- help.naver.com — Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide | ZeroHedge
- www.zacks.com — How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 ...
- www.cbsnews.com — More people now use GLP-1s for weight loss than for other ...
- www.foreignpolicyjournal.com — NIH-Funded Study Finds GLP-1 Drugs Slow Aging In Mice ...
-
Government Study Finds GLP-1 Drugs Slow Aging in Mice
A government-funded study discovered that GLP-1 medications slow the aging process in mice. This follows reports from Eli Lilly CEO Dave Ricks that 700,000 new senior patients began GLP-1 treatments following Medicare coverage expansions, with 70% using Lilly products. The GLP-1 market generated $79 billion in 2025 and may hit $190 billion by 2035. These medications helped Eli Lilly become the first pharmaceutical company to reach a $1 trillion valuation.
Why it matters
The expansion of Medicare coverage has significantly increased access for elderly populations. Evidence of anti-aging properties could expand the clinical application of these drugs beyond diabetes and obesity.
What is confirmed
- Eli Lilly is the first pharmaceutical company to reach a $1 trillion valuation.
- The GLP-1 market earned $79 billion in 2025.
Still unconfirmed
- A government-funded study found GLP-1 drugs slow the aging process in mice.
What to watch next
- Human clinical trials for anti-aging properties
- Updated Medicare reimbursement data for 2026
confidence 70%Sources used for this update (4)
- www.glp1authority.com — GLP-1 News & Updates — Daily Summaries | GLP1Authority
- www.biospace.com — GLP-1 - BioSpace
- forbesliberia.com — GLP-1s Took Eli Lilly To $1 Trillion. CEO Dave Ricks Is ...
- www.fool.com — Novo Nordisk and Eli Lilly Just Got Some Fantastic News
-
Eli Lilly CEO: 700K seniors started GLP-1s after Medicare coverage
Eli Lilly CEO Dave Ricks reported that 700,000 new senior patients started GLP-1 medications after Medicare coverage expansions, with 70% of them on Lilly drugs. The GLP-1 market made $79 billion in sales in 2025 and could reach $190 billion by 2035. Lilly's success with these drugs has made it the first $1 trillion pharma company.
Why it matters
The GLP-1 market is rapidly growing, with significant implications for obesity and diabetes treatment. Eli Lilly's dominance in this market is evident, but the company faces risks associated with its reliance on these blockbuster drugs. Researchers are also exploring potential anti-aging properties of these medications.
What is confirmed
- 700,000 new senior patients started GLP-1 medications following Medicare coverage expansions.
- 70% of new senior GLP-1 patients are on Eli Lilly drugs.
- GLP-1 drugs made $79 billion in sales in 2025.
- The GLP-1 market could reach $190 billion by 2035.
- Eli Lilly is the first $1 trillion pharma company, driven by its blockbuster weight-loss and diabetes drugs.
Still unconfirmed
- One-third of new GLP-1 pill patients are taking Foundayo.
- GLP-1 medications may affect measures of biological age, potentially reversing biologic aging by two to three years.
What to watch next
- Eli Lilly's financial reports for 2026
- Further research on the anti-aging properties of GLP-1 medications
- Medicare coverage expansions for GLP-1s
confidence 95%Sources used for this update (2)
- explodingtopics.com — GLP-1 Market Size and Sales Statistics (October 2026)
- finance.yahoo.com — GLP-1s Took Eli Lilly To $1 Trillion. CEO Dave Ricks Is ...
-
Eli Lilly CEO Confirms 700,000 New Seniors On GLP-1s
Eli Lilly chief executive Annika Kim Constantino reported that 700,000 new senior patients started GLP-1 medications following Medicare coverage expansions, with Lilly capturing seventy percent of that adoption. Concurrently, one-third of new GLP-1 pill patients are taking Foundayo, according to the executive. In the broader market, weight-loss drugs are altering consumer behavior while researchers investigate potential anti-aging properties. New data presented at a Boston aging meeting indicates these medications appear to affect measures of biological age, potentially reversing biologic aging by two to three years.
Why it matters
Blockbuster weight-loss and diabetes treatments are expanding beyond initial obesity indications as drugmakers gather new evidence regarding longevity. Research presented in Boston links the medications to slowing the body aging processes. These developments arrive while regulatory and market dynamics shift, including recent policy changes affecting healthcare enrollment under the Trump administration.
What is confirmed
- Annika Kim Constantino reported that 700,000 seniors started GLP-1 medications following Medicare coverage expansions, with Lilly capturing seventy percent of that adoption.
- Annika Kim Constantino stated that one-third of new GLP-1 pill patients are taking Foundayo.
- Research presented at an aging meeting in Boston indicates that GLP-1 weight-loss drugs affect biological age measures.
Still unconfirmed
- Drug companies claim that GLP-1 medications can reverse biologic aging by two to three years.
What to watch next
- Further clinical data regarding the anti-aging and longevity effects of GLP-1 medications
- Additional adoption and sales metrics for Lilly drugs and Foundayo following Medicare coverage expansions
confidence 100%Sources used for this update (6)
- www.cnbc.com — Health and Science
- www.technologyreview.com — We’re still figuring out the side effects of GLP-1 weight-loss drugs
- trendspider.com — LLY (Eli Lilly and Company) – Technical Charts and Market Data – TrendSpider
- nypost.com — GLP-1 drugs can ‘reverse biologic aging’ by two to three years, say drug companies
- finance.yahoo.com — As GLP-1 Drugs Change How People Eat, Drugmakers Collect and ...
- www.cnn.com — Could GLP-1 drugs be anti-aging medications? - CNN
-
Eli Lilly CEO Cites 700,000 New Seniors on GLP-1s
Eli Lilly maintains its dominant position in the obesity drug market after Medicare coverage expansions brought 700,000 new seniors onto GLP-1 medications, with Lilly capturing seventy percent of that adoption. Financial metrics reflect this strength through second-quarter revenue climbing 48 percent to $22.97 billion and a market valuation reaching approximately $1.02 trillion. Meanwhile, the company advances its pipeline by planning a retatrutide filing for the first quarter of 2027 and seeing acceleration in oral prescriptions, alongside new longevity data entering the conversation alongside rival Novo Nordisk.
Why it matters
Medicare policy shifts have triggered massive adoption among older adults, fueling record financial metrics for dominant manufacturers. Both Eli Lilly and competitor Novo Nordisk are expanding their clinical scope as longevity data brings the drug class into broader health discussions. This wave of utilization coincides with aggressive pipeline developments, including upcoming filing targets and oral medication growth.
What is confirmed
- Eli Lilly and Novo Nordisk have released GLP-1 longevity data, signaling the drug class may have implications well beyond weight loss.
What to watch next
- Retatrutide regulatory filing planned for the first quarter of 2027
- Further updates on oral prescription acceleration and Medicare adoption rates
confidence 90%Sources used for this update (3)
- www.cnbc.com — Companies - CNBC
- finance.yahoo.com — Eli Lilly Just Announced Something Big. Here’s What It Means ...
- agetech.com — GLP-1 Drugs Enter the Longevity Conversation as Lilly and ...
-
Eli Lilly Leads GLP-1 Market as Senior Medicare Uptake Surges
Eli Lilly maintains a dominant position in the obesity drug market as 700,000 new seniors begin taking GLP-1 medications following Medicare coverage expansions, with Lilly capturing seventy percent of that adoption. Financial metrics reflect this strength, with second-quarter revenue climbing 48 percent to $22.97 billion and a market valuation reaching approximately $1.02 trillion. Meanwhile, the company advances its pipeline by planning a retatrutide filing for the first quarter of 2027 and seeing acceleration in oral prescriptions.
Why it matters
The expansion of Medicare coverage for GLP-1 treatments has triggered a massive wave of senior adoption, cementing Eli Lilly's market leadership over competitors like Novo Nordisk. This commercial momentum coincides with ongoing clinical developments across Lilly's portfolio, including combination trials and pipeline adjustments. Competitors are also shifting strategies as regulatory decisions loom for alternative obesity and diabetes therapies.
What is confirmed
- 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs.
- Lilly's Q2 revenue rose 48% to $22.97 billion and its market value is about $1.02 trillion.
- Lilly plans to file retatrutide in Q1 2027.
- Total prescriptions for Eli Lilly's oral GLP-1 receptor agonist surged about 21% to 64,268 during last week.
- Foghorn Therapeutics discontinued development of an experimental cancer drug partnered with Eli Lilly after it failed to show enough benefit in an early-stage trial.
Still unconfirmed
- Novo Nordisk faces its next big test with the FDA decision on CagriSema, expected in Q4 2026, alongside its Wegovy pill.
What to watch next
- FDA decision on CagriSema in Q4 2026
- Eli Lilly retatrutide filing in Q1 2027
- Phase 3 trial launch for EloraTZP before the end of the year
confidence 100%Sources used for this update (3)
- www.onedayadvisor.com — Eli Lilly vs. Novo Nordisk — The GLP‑1 Market Showdown (2026 ...
- www.cafepharma.com — Eli Lilly | Cafepharma
- biztoc.com — 700,000 Seniors Have Started GLP-1s Through Medicare. Now ...
-
Eli Lilly Expands Pediatric Indications For Olumiant Following FDA Decision
Eli Lilly and Company received U.S. FDA approval for Olumiant, a once-daily pill, to treat pediatric patients 12 years of age and older with severe alopecia areata. This regulatory decision expands the medication's label beyond its established adult indications in moderately to severely active rheumatoid arthritis and severe alopecia areata. Meanwhile, the pharmaceutical company continues to maintain a leading position in the obesity drug market through its GLP-1 treatments, which have been adopted by hundreds of thousands of seniors under recent Medicare coverage expansions.
Why it matters
The expansion of Olumiant for pediatric patients highlights the pharmaceutical company's ongoing efforts to grow its product portfolio beyond its primary revenue drivers. This regulatory milestone adds a new treatment option for adolescents suffering from severe hair loss conditions. The company's broader market momentum relies heavily on both its newly approved specialty medicines and its dominant share of the burgeoning senior obesity drug sector.
What is confirmed
- On September 25, Eli Lilly and Company announced that the U.S. FDA approved Olumiant for pediatric patients 12 years of age and older with severe alopecia areata.
- Olumiant is a once-daily pill previously approved for adult indications in moderately to severely active rheumatoid arthritis and severe alopecia areata.
What to watch next
- Commercial launch and market uptake of Olumiant for pediatric patients
- Further regulatory decisions regarding the expansion of Eli Lilly product labels
confidence 100%Sources used for this update (10)
- en.wikipedia.org — Eli (biblical figure) - Wikipedia
- finance.yahoo.com — Eli Lilly and Company (LLY) is Expanding Beyond its Biggest Growth Drivers. Can it Sustain the Momentum?
- en.wikipedia.org — Eli (2019 film) - Wikipedia
- www.gotquestions.org — Who was Eli in the Bible? - GotQuestions.org
- elireview.com — Eli Review
- www.christianity.com — Who Was Eli in the Bible? His Life and Story - Christianity
- nypost.com — Patriots tight end Eli Raridon’s son dies in tragic reveal
- www.eli.org — ELI Home | Environmental Law Institute
- biblehub.com — Topical Bible: Eli
- www.youtube.com — Eli | Official Trailer | Netflix - YouTube
-
Eli Lilly Captures 70% of New Senior GLP-1 Market
Eli Lilly CEO David Ricks reports that approximately 700,000 seniors have started GLP-1 treatments since Medicare began covering obesity drugs in July. Roughly 70% of these new patients are using Lilly products over competitors. The rollout occurs through a temporary Medicare Bridge program that allows eligible beneficiaries to acquire obesity treatments for a $50 monthly co-pay. Meanwhile, taxpayers cover about $195 per patient each month. Rival manufacturer Novo Nordisk recently presented a growth strategy at its Capital Markets Day, though some analysts indicate Lilly holds advantages to maintain its position at the top of the obesity drug market.
Why it matters
The rollout of Medicare coverage for weight-loss drugs marks a significant shift in patient access and commercial competition. Eli Lilly and Novo Nordisk are locked in an ongoing race for market dominance in the obesity and diabetes drug sector. Additional market pressures include state Medicaid programs expanding coverage and potential financial headwinds for insurers.
What is confirmed
- Eli Lilly CEO David Ricks states that about 700,000 new seniors have started GLP-1 treatment since Medicare began covering obesity drugs in July.
- Roughly 70% of the seniors starting GLP-1 treatment through the Medicare rollout are using Lilly medicines.
- The temporary Medicare Bridge program allows eligible beneficiaries to obtain obesity treatments for a $50 monthly co-pay.
- Taxpayers cover about $195 per patient each month under the Medicare Bridge scheme.
- Novo Nordisk presented a growth strategy at its Capital Markets Day that failed to convince investors.
Still unconfirmed
- Some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
- Two specific deadlines related to the Medicare Bridge program could change the $50 copay structure.
What to watch next
- Upcoming deadlines related to the Medicare Bridge program and co-pay structure.
- Further market share data between Eli Lilly and Novo Nordisk.
- Progress on AstraZeneca's once-daily pill in late-stage trials.
confidence 95%Sources used for this update (8)
- www.cnbc.com — Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
- rocketnews.com — Novo is betting on its next chapter as Eli Lilly gains more ...
- rocketnews.com — Eli Lilly CEO says 700,000 new seniors have started GLP-1s ...
- finance.yahoo.com — A New Wave of Senior Patients Could Extend Lilly’s GLP-1 ...
- www.ibtimes.co.uk — 700,000 Seniors Start GLP-1 Weight-Loss Drugs — but US ...
- www.erikseninsurance.com — Medicare’s GLP-1 Coverage Is Off to a Fast Start
- finance.yahoo.com — 700,000 Seniors Have Started GLP-1s Through Medicare. Now ...
- www.cnbc.com — Biotechnology and Pharmaceuticals - CNBC
-
Eli Lilly Leads GLP-1 Adoption Among Seniors Following Medicare Coverage
Eli Lilly CEO reports that 700,000 seniors began using GLP-1 obesity treatments after gaining Medicare coverage, with 70% of those patients choosing Lilly drugs. To support growth, the company has broken ground on a $6.5 billion manufacturing facility in Houston's Generation Park, planned for 2030. This site is one of ten U.S. manufacturing locations announced since 2020. Additionally, some state Medicaid programs are expanding to cover GLP-1 weight loss medications, while the Medicare GLP-1 Bridge program is viewed as a potential financial headwind for insurers.
Why it matters
GLP-1 medications have shifted from diabetes management to broader obesity care. Increased government coverage through Medicare and Medicaid expands the patient base significantly. The scale of this demand requires massive infrastructure investment to prevent supply shortages.
What is confirmed
- 700,000 seniors started GLP-1 obesity treatments under Medicare, and 70% chose Eli Lilly drugs.
- Eli Lilly is breaking ground on a $6.5 billion facility in Houston's Generation Park planned for 2030.
- The Houston site is one of ten U.S. manufacturing sites Eli Lilly has announced since 2020.
Still unconfirmed
- The Medicare GLP-1 Bridge program is a potential headwind for insurers.
- A state Medicaid program will now cover GLP-1 weight loss drugs.
- Eli Lilly announced a $15 million contribution to San Jacinto College.
What to watch next
- Updates on the production timeline for the Houston facility
- Data on the impact of the Medicare GLP-1 Bridge program on insurer costs
- Further state-level Medicaid coverage expansions for obesity drugs
confidence 90%Sources used for this update (10)
- KHOU — Eli Lilly is breaking ground in Houston on a facility planned for 2030
- CNBC — Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
- Modern Healthcare — Medicare GLP-1 Bridge program a potential headwind for insurers
- Pluang — 700,000 seniors start GLP-1 obesity treatments under Medicare, 70% choose Eli Lilly drugs
- The American Journal of Managed Care® (AJMC®) — Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
- The Chicago Crusader — State Medicaid program will now cover GLP-1 weight loss drugs
- Briefs Finance — Medicare Spurs 700K Seniors to GLP-1s; Lilly Leads
- abc13.com — Lilly breaks ground in Generation Park, announces $15M contribution to San Jacinto College
- PR Newswire — Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
- Yahoo Finance — Eli Lilly Breaks Ground on $6.5B Generation Park Facility
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community